Introduction The global and domestic initiatives to end the human immunodeficiency virus (HIV) epidemic by the year 2030 are currently navigating a highly complex paradigm defined by unprecedented scientific breakthroughs and simultaneous sociopolitical regressions. Over the past four decades, advancements in antiretroviral therapy and pre-exposure prophylaxis have transformed HIV from an invariably fatal diagnosis into a manageable chronic condition. Epidemiological data thr

Introduction to the Next Generation of HIV Immunization The pursuit of a highly effective prophylactic vaccine against the human immunodeficiency virus (HIV) remains one of the most formidable challenges in modern biomedical science. For more than four decades, the staggering genetic diversity of the virus, its rapid mutation rate, and its sophisticated immune evasion mechanisms have thwarted traditional vaccine design strategies. The primary goal of contemporary HIV vaccine

Introduction As the acute crisis of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has transitioned into an endemic reality, the focus of the global medical and scientific communities has increasingly shifted toward the chronic sequelae of the infection. Post-acute sequelae of SARS-CoV-2 (PASC), widely referred to as Long COVID, has emerged as a complex, heterogeneous, and debilitating condition that currently affects tens of millions of people worl

Introduction: The Convergence of Ideology and Austerity In January 2026, the trajectory of the HIV/AIDS epidemic in the United States shifted violently. For decades, the national strategy relied on a bipartisan consensus that prioritized viral suppression through robust federal funding and state-level cooperation. That consensus has fractured. A simultaneous contraction of federal support, delineated in the Trump administration's Fiscal Year 2026 budget, and a drastic restruc